Ritonavir acts synergistically with panobinostat to enhance histone acetylation and inhibit renal cancer growth

Younes A, Sureda A, Ben-Yehuda D, et al: Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 30:2197–2203. 2012.

Ghobrial IM, Campigotto F, Murphy TJ, et al: Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia. Blood. 121:1296–1303. 2013.PubMed/NCBI

Morita S, Oizumi S, Minami H, et al: Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors. Invest New Drugs. 30:1950–1957. 2012. View Article : Google Scholar : PubMed/NCBI

Hainsworth JD, Infante JR, Spigel DR, et al: A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Cancer Invest. 29:451–455. 2011.PubMed/NCBI

Eagling VA, Back DJ and Barry MG: Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol. 190–194. 1997.PubMed/NCBI

Hamberg P, Woo MM, Chen LC, Verweij J, Porro MG, Zhao L, Li W, van der Biessen D, Sharma S, Hengelage T and de Jonge M: Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. Cancer Chemother Pharmacol. 68:805–813. 2011. View Article : Google Scholar : PubMed/NCBI

Marks P, Rifkind RA, Richon VM, Breslow R, Miller T and Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 1:194–202. 2001. View Article : Google Scholar : PubMed/NCBI

Wade PA: Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum Mol Genet. 10:693–698. 2001. View Article : Google Scholar

Grunstein M: Histone acetylation in chromatin structure and transcription. Nature. 389:349–352. 1997. View Article : Google Scholar : PubMed/NCBI

Cress WD and Seto E: Histone deacetylases, transcriptional control, and cancer. J Cell Physiol. 184:1–16. 2000. View Article : Google Scholar : PubMed/NCBI

Yoo CB and Jones PA: Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 5:37–50. 2006. View Article : Google Scholar : PubMed/NCBI

Hrzenjak A, Moinfar F, Kremser ML, et al: Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther. 5:2203–2210. 2006. View Article : Google Scholar

Gui CY, Ngo L, Xu WS, Richon VM and Marks PA: Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA. 101:1241–1246. 2004. View Article : Google Scholar : PubMed/NCBI

Dewan MZ, Tomita M, Katano H, et al: An HIV protease inhibitor, ritonavir targets the nuclear factor-kappaB and inhibits the tumor growth and infiltration of EBV-positive lymphoblastoid B cells. Int J Cancer. 124:622–629. 2009. View Article : Google Scholar : PubMed/NCBI

Srirangam A, Mitra R, Wang M, et al: Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clin Cancer Res. 12:1883–1896. 2006. View Article : Google Scholar : PubMed/NCBI

Sato A and Asano T, Ito K and Asano T: 17-allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1. Int J Oncol. 41:46–52. 2012.PubMed/NCBI

Bali P, Pranpat M, Bradner J, et al: Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem. 280:26729–26734. 2005. View Article : Google Scholar : PubMed/NCBI